Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas

Journal of Experimental and Clinical Cancer Research

Volumn 18, Issue 3, 1999, Pages 363-367

  Soda, G ^a   Antonaci, A ^a   Bosco, D ^a   Nardoni, S ^a   Melis, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Oncogenes; Prognostic markers; Thyroid carcinoma

Indexed keywords

CELL SURFACE RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RAS PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL SURVIVAL; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RISK FACTOR; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; APOPTOSIS; CARCINOMA; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, ERBB-2; GENES, P53; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032757963     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Reed J.C.: Mini-review: Cellular mechanism of diseases series. The Journal of Cell Biology 1994; 124: 1-6.
2. Chetty R ., O'Leary J.J., Biddolph S.C. and Gatter K.C.: Immunohistochemical detection of p53 and bcl-2 proteins in Hashimoto's thyroiditis and primary thyroid lymphomas. J. Clin. Pathol. 1995; 48: 239-241.
3. Tsujimoto Y., Cossman J., Jaffe E., Croce C.: Involvement of bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-1443.
4. Cleary M.L., Galili N., Sklar J.: Detection of a second t(14:18) breakpoint cluster region in human follicular lymphomas. J. Exp. Med. 1986; 164: 315-320.
5. Pilotti S., Collini P., Rilke F., Cattoretti G., Del Bo R. and Pierotti M.A.: bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J. of Pathlogy, 1994; 172: 337-342.
6. Pollina L., Pacini R, Fontanini G., Vignati S., Bevilacqua G. and Basolo F.: bcl-1, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. British Journal of Cancer, 1996; 73: 139-143.
7. Hockenbery D.M., Zutter M., Hickey W., Nahm M., Korsmeyer S.J.: Bcl-2 protein is topographicallyrestricted in tissues characterised by apoptotic cell death. Proc. Natl.Acad. Sci. USA 1991; 88: 6961-6965.
8. Coussens L., Yang-Feng T.L., Liao Y.C. et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
9. Akiyama T., Sudo C., Ogawara H., Toyoshima K., Yamamoto T.: The product of the human c-erbB-2 gene: A 185 kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646.
10. Slamon D.J., Wong S.G., Levin W.J. et al.: Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
11. Van de Vijver M.J., Mooi W.J., Wisman P., Peterse J.L., Nusse R.: Immunohistochemical detection of the neu protein in tissue sectionsof human breast tumors with amplified neu DNA. Oncogene 1988; 2: 175-178.
12. Winstanley J., Cooke T., Murray G.D. et al.: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br. J. Cancer 1991; 63: 447-450.
13. Gullick W.J., Love S.B., Wright C. et al.: c-erbB-2protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer 1991; 63: 434-438.
14. Holm R., Nesland J.M.: Retinoblastoma and p53 tumour suppressor gene protein expression in carcinoma of the thyroid gland. Journal of Pathology 1994; 172: 267-272.
15. Finlay C.A., Hinds P.W., Tan T.H., Eliyahu D., Oren M., Levine A.J.: Activating mutations for transformation by p53 produce a geneproduct that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 1988; 8: 531-539.
16. Levine A.J., Perry M.E., Chang A. et al. : The 1993Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Brithish Journal of Cancer, 1994; 69: 409-4516.
17. Dobashi Y., Sakamoto A., Sugimura H. et al.: overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am. J. of Surg. Pathol., 1993; 17(4): 375-381.
18. Soares P., Cameselle-Teijeiro J. and Sobrinho-Simoes M.: Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology, 1994; 24: 205-210.
19. El-Deiry W.S., Tokino T., Velculescu V.E.et al.: WAF1, a potential mediator ofp53 tumour suppression. Cell 1993; 75: 817-825.
20. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D.: p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
21. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J.: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
22. Shi Y., Zou M., Farid N.R. and Al-Sedairy S.T.: Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. British Journal of Cancer, 1996; 74: 1336-1341.
23. Li R., Waga S., Hannon G.J., Beach D., Stillmann B.: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994; 371: 534-537.
24. Donghi R., Longoni A., Pilotti S., Michieli P., Porta G.D., Pierotti M.A.: Gene p53 mutation are restricted to poorly and undifferentiated carcinoma of thyroid gland. J. Clin. Invest. 1993; 91: 1753-1760.
25. Lemoine N.R., Wyllie F.S., Lillehaug J.R. et al.: Absence of abnormalities of the c-erbB-1 and c-erbB-2 proto-oncogenes in human thyroid neoplasia. Eur. J. Cancer 1990; 26: 777-779.
26. Haugen D.F., Akslen L.A., Varhaug J.E. and Lillehaug J.: Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br. J. Cancer 1992; 65: 832-837.
27. Mincione G., Cirafici A.M., Lazzareschi D., Pepe S., Ciardiello F., Colletta G.: Loss of thyrotropin regulation and transforming growth factorarrest in ß-induced growth arrest in erbB-2 overexpressing rat thyroid cells. Cancer Res. 1993; 53. 5548-53.
28. Yonisch-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A. andOren M.: Wild type p53 induces apoptosisof myeloid leukemyc cells that is inhibited by interleukin-6. Nature 1991; 352: 345-347.
29. Hockenbery D., Nunez G., Milliman C, Schreiber R.D. and Korsmeyer S.J.: bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.